Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT06474481

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

First Posted Date
2024-06-24
Last Posted Date
2024-06-24
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
29
Registration Number
NCT06470633

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

First Posted Date
2024-06-21
Last Posted Date
2024-06-21
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT06468943
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Nanjing, China

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

First Posted Date
2024-06-07
Last Posted Date
2024-11-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
24
Registration Number
NCT06447987
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

First Posted Date
2024-06-04
Last Posted Date
2024-06-04
Lead Sponsor
Ruijin Hospital
Target Recruit Count
152
Registration Number
NCT06441097

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

First Posted Date
2024-05-30
Last Posted Date
2024-12-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
47
Registration Number
NCT06434363
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

First Posted Date
2024-05-22
Last Posted Date
2024-11-19
Lead Sponsor
Celgene
Target Recruit Count
90
Registration Number
NCT06425302
Locations
🇺🇸

Local Institution - 0020, New Brunswick, New Jersey, United States

🇩🇪

Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany

🇮🇹

Local Institution - 0179, Rozzano, Milano, Italy

and more 65 locations

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

First Posted Date
2024-05-16
Last Posted Date
2024-12-05
Lead Sponsor
Acepodia Biotech, Inc.
Target Recruit Count
30
Registration Number
NCT06415487
Locations
🇺🇸

University of California San Diego, San Diego, California, United States

🇺🇸

Texas Oncology, Dallas, Texas, United States

🇨🇳

Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan

and more 6 locations

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

First Posted Date
2024-05-14
Last Posted Date
2024-06-10
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
60
Registration Number
NCT06412497
Locations
🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

First Posted Date
2024-05-14
Last Posted Date
2024-12-19
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
450
Registration Number
NCT06413498
Locations
🇺🇸

UCLA Department of Medicine-Hematology/Oncology, Santa Monica, California, United States

🇺🇸

Baptist Cancer Center, Memphis, Tennessee, United States

🇦🇺

Epworth HealthCare, Richmond, Victoria, Australia

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy